Gamida Cell - GMDA Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings or view top-rated stocks.

5 brokers have issued twelve-month price targets for Gamida Cell's shares. Their GMDA share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $12.80 in the next year. This suggests a possible upside of 666.5% from the stock's current price.
View analysts price targets for GMDA or view top-rated stocks among Wall Street analysts.

Gamida Cell's stock was trading at $1.29 at the beginning of 2023. Since then, GMDA shares have increased by 29.5% and is now trading at $1.67.
View the best growth stocks for 2023 here.

Gamida Cell saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 4,590,000 shares, an increase of 15.3% from the December 31st total of 3,980,000 shares. Based on an average daily trading volume, of 522,700 shares, the days-to-cover ratio is presently 8.8 days.
View Gamida Cell's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our GMDA earnings forecast.

Gamida Cell Ltd. (NASDAQ:GMDA) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.26%), Stock Yards Bank & Trust Co. (0.07%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends.

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMDA stock can currently be purchased for approximately $1.67.

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $124.21 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

The company employs 166 workers across the globe.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (713) 400-6400 or via email at irpr@gamida-cell.com.